HM2014-26 DT2219 Immunotoxin for the Treatment of Relapsed or Refractory CD19 (+) and/or CD 22 (+) B-lineage Leukemia or Lymphoma
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs DT2219ARL (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 31 May 2019 Results published in conjunction with the 55th Annual Meeting of the American Society of Clinical Oncology
- 30 May 2019 Topline consolidated results of two phase I/II trials (NCT00889408 and NCT02370160) presented in a GT Biopharma media release.
- 29 May 2019 Results presented in the GT Biopharma media release.